IRF3-dependent type I interferon response in B cells regulates CpG-mediated antibody production

被引:28
作者
Oganesyan, Gagik [1 ,2 ]
Saha, Supriya K. [1 ,2 ]
Pietras, Eric M. [1 ]
Guo, Beichu [1 ]
Miyahira, Andrea K. [1 ]
Zarnegar, Brian [1 ]
Cheng, Genhong [1 ,3 ,4 ]
机构
[1] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Med Scientist Training Program, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA
[4] Univ Calif Los Angeles, Johnsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA
关键词
D O I
10.1074/jbc.M704755200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Hypomethylated CpG oligonucleotides (CpG) are not only potent adjuvants for enhancing adaptive immune responses but may also play a critical role in the development of autoimmune diseases such as Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE). Here we provide evidence that, in addition to dendritic cells, murine B lymphocytes also exhibit a type I IFN response to CpG-B. Unlike dendritic cells, B cell-mediated type I IFN induction depended on the transcription factor IRF3, but similar to dendritic cells this pathway was independent of the IRF3 kinase TBK1. Utilizing type I IFN receptor-deficient mice, we were able to demonstrate that this IFN pathway enhanced Syndecan-1 expression and IgM production and was required for IgG2a production following CpG-B stimulation. Overall, our findings identify a unique IFN pathway in B cells that may play a central role in mediating B cell biology in response to CpG, potentially implicating this pathway in autoantibody production and the pathogenesis of certain autoimmune diseases.
引用
收藏
页码:802 / 808
页数:7
相关论文
共 53 条
[1]  
ARNOLD LW, 1988, J IMMUNOL, V140, P4355
[2]  
ARNOLD LW, 1983, J IMMUNOL, V131, P2064
[3]   Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus [J].
Baechler, EC ;
Batliwalla, FM ;
Karypis, G ;
Gaffney, PM ;
Ortmann, WA ;
Espe, KJ ;
Shark, KB ;
Grande, WJ ;
Hughes, KM ;
Kapur, V ;
Gregersen, PK ;
Behrens, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (05) :2610-2615
[4]   Utility of the housekeeping genes 18S rRNA, β-actin and glyceraldehyde-3-phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes [J].
Bas, A ;
Forsberg, G ;
Hammarström, S ;
Hammarström, ML .
SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 2004, 59 (06) :566-573
[5]  
Behar S M, 1989, Int Rev Immunol, V5, P23, DOI 10.3109/08830188909086988
[6]   Type I Interferon controls the onset and severity of autoimmune manifestations in lpr mice [J].
Braun, D ;
Geraldes, P ;
Demengeot, J .
JOURNAL OF AUTOIMMUNITY, 2003, 20 (01) :15-25
[7]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[8]   Type I IFN receptor signals directly stimulate local B cells early following influenza virus infection [J].
Coro, Elizabeth S. ;
Chang, W. L. William ;
Baumgarth, Nicole .
JOURNAL OF IMMUNOLOGY, 2006, 176 (07) :4343-4351
[9]   CpG DNA in the prevention and treatment of infections [J].
Dalpke, A ;
Zimmermann, S ;
Heeg, K .
BIODRUGS, 2002, 16 (06) :419-431
[10]   IFNs and STATs in innate immunity to microorganisms [J].
Decker, T ;
Stockinger, S ;
Karaghiosoff, M ;
Müller, M ;
Kovarik, P .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 109 (10) :1271-1277